Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

European Journal of Cancer

Volumn 40, Issue 7, 2004, Pages 939-950

  Van Kuilenburg, André B P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Dihydropyrimidine dehydrogenase; DPYD; Fluorouracil; Mutations; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; Polymorphisms

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED; SORIVUDINE; TEGAFUR; URACIL DERIVATIVE;

AREA UNDER THE CURVE; BLADDER CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CATABOLISM; COLORECTAL CANCER; DNA POLYMORPHISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LETHAL DOSE; LUNG NON SMALL CELL CANCER; MOUTH CARCINOMA; NEUTROPENIA; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMACH CANCER;

EID: 1942453306     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.12.004     Document Type: Article

References (125)

1. Ries L.A.G., Wingo P.A., Miller D.S.et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 88:2000;2398-2424.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345, 939-944.
3. Simmonds P.C. Palliative chemotherapy for advanced colorectal cancer. systematic review and meta-analysis. Colorectal Cancer Collaborative Group Br. Med. J. 321:2000;531-535.
4. Jonker D.J., Maroun J.A., Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer. a meta-analysis of randomized controlled trials Br J Cancer. 82:2000;1789-1794.
5. Magné N., François E., Broisin L.et al. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly. results of a 10-year experience Am. J. Clin. Oncol. 25:2002;126-130.
6. Meta-analysis Group In Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.
7. Adlard J.W., Richman S.D., Seymour M.T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 3:2002;75-82.
8. Köhne C.H., Cunningham D., Di Costanzo F.et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer. results of a multivariate analysis of 3825 patients Ann. Oncol. 13:2002;308-317.
9. Volk J., Reinke F., van Kuilenburg A.B.P.et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann. Oncol. 12:2001;569-571.
10. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. a meta-analysis of prospective studies JAMA. 279:1998;1200-1205.
11. Meta-Analysis Group In Cancer Toxicity of fluorouracil in patients with advanced colorectal cancer. effect of administration schedule and prognostic factors J. Clin. Oncol. 16:1998;3537-3541.
12. Mattison L.K., Soong R., Diasio R.B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 3:2002;485-492.
13. Gardiner S.J., Begg E.J., Robinson B.A. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React. Toxicol. Rev. 21:2002;1-16.
14. van Kuilenburg A.B.P., De Abreu R.A., van Gennip A.H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem. 40:2003;41-45.
15. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48:1990;381-395.
16. Grem J.L. 5-Fluorouracil. forty-plus and still ticking. A review of its preclinical and clinical development Invest. New Drugs. 18:2000;299-313.
17. Schuetz J.D., Diasio R.B. The effect of 5-fluorouracil on DNA chain elongation in intact bone marrow cells. Biochem. Biophys. Res. Commun. 133:1985;361-367.
18. Schuetz J.D., Collins J.M., Wallace H.J., Diasio R.B. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res. 46:1986;119-123.
19. Kessel D. Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil. Cancer Res. 40:1980;322-324.
20. Peters G.J., Pinedo H.M., Ferwerda W., de Graaf T.W., van Dijk W. Do antimetabolites interfere with the glycosylation of cellular glycoconjugates? Eur. J. Cancer. 26:1990;516-523.
21. Leichman C.G., Lenz H.J., Leichman L.et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:1997;3223-3229.
22. Aschele C., Debernardis D., Casazza S.et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17:1999;1760-1770.
23. Salonga D., Danenberg K.D., Johnson M.R.et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:2000;1322-1327.
24. Iacopetta B., Grieu F., Joseph D., Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer. 85:2001;827-830.
25. Sobrero A.F., Aschele C., Bertino J.R. Fluorouracil in colorectal cancer - a tale of two drugs. implications for biochemical modulation J. Clin. Oncol. 15:1997;368-381.
26. Schüller J., Cassidy J., Dumont E.et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45:2000;291-297.
27. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206.
28. Naguib F.N.M., el Kouni M.H. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45:1985;5405-5412.
29. van Kuilenburg A.B.P., van Lenthe H., Blom M.J., Mul E.P.J., van Gennip A.H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells. major implications for the detection of partly deficient patients Br. J. Cancer. 79:1999;620-626.
30. Etienne M.C., Chatelut E., Pivot X.et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur. J. Cancer. 34:1998;92-97.
31. Stéphan F., Etienne M.C., Wallays C., Milano G.A., Clergue F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am. J. Med. 99:1995;685-688.
32. Chazal M., Etienne M.C., Renée N., Bourgeon A., Richelme H., Milano G.A. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res. 2:1996;507-510.
33. Harris B.E., Song R., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
34. Porsin B., Formento J.L., Filipski E.et al. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver. comparison between enzyme activity and gene expression Eur. J. Cancer. 39:2003;822-828.
35. Grem J.L., Yee L.K., Venzon D.J., Takimoto C.H., Allegra C.J. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol. 40:1997;117-125.
36. van Kuilenburg A.B.P., Poorter R.L., Peters G.J.et al. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Advances in Experimental Medicine & Biology. 431:1998;811-816.
37. Raida M., Kliche K.O., Schwabe W.et al. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J. Cancer Res. Clin. Oncol. 128:2002;96-102.
38. Takimoto C.H., Yee L.K., Venzon D.J.et al. High inter- and intrapatient variantion in 5-Florouracil plama concentrations during a prolonged drug infusion. Clin. Cancer Res. 5:1999;1347-1352.
39. Etienne M.C., Lagrange J.L., Dassonville O.et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12:1994;2248-2253.
40. Di Paolo A., Danesi R., Falcone A.et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann. Oncol. 12:2001;1301-1306.
41. Terashima M., Irinoda T., Kawamura H.et al. Intermittent FLDP. 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale Cancer Chemother. Pharmacol. 51:2003;240-246.
42. Maring J.G., van Kuilenburg A.B.P., Haasjes J.et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer. 86:2002;1028-1033.
43. Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81:1988;47-51.
44. Okuda H., Nishiyama T., Ogura K.et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. 25:1997;270-273.
45. Diasio R.B. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. J. Clin. Pharmacol. 46:1998;1-4.
46. McLeod H.L., Sludden J., Murray G.I.et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer. 77:1998;461-465.
47. Vokes E.E., Mick R., Kies M.S.et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J. Clin. Oncol. 14:1996;1663-1671.
48. Saeki H., Ito S., Futatsugi M., Kimura Y., Ohga T., Sugimachi K. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. Anticancer Res. 22:2002;3789-3792.
49. Beck A., Etienne M.C., Chéradame S.et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer. 30A:1994;1517-1522.
50. Scherf U., Ross D.T., Waltham M.et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244.
51. Ishikawa Y., Kubota T., Otani Y.et al. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin. Cancer Res. 5:1999;883-889.
52. Takebe N., Zhao S.C., Ural A.U.et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 8:2001;966-973.
53. Johnston S.J., Ridge S.A., Cassidy J., McLeod H.L. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res. 5:1999;2566-2570.
54. Grem J.L., Danenberg K.D., Behan K.et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 7:2001;999-1009.
55. Miyamoto S., Ochiai A., Boku N.et al. Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int. J. Oncol. 18:2001;705-713.
56. Uetake H., Ichikawa W., Takechi T., Fukushima M., Nihei Z., Sugihara K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin. Cancer Res. 5:1999;2836-2839.
57. Kornmann M., Schwabe W., Sander S.et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels. predictors for survival in colorectal cancer patients receiving adjuvant 5-Fluorouracil Clin. Cancer Res. 9:2003;4116-4124.
58. Ikeguchi M., Makino M., Kaibara N. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. Langenbecks Arch. Surg. 387:2002;240-245.
59. Etienne M.C., Chéradame S., Fischel J.L.et al. Response to fluorouracil therapy in cancer patients. the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13:1995;1663-1670.
60. Etienne M.C., Pivot X., Formento J.L.et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br. J. Cancer. 79:1999;1864-1869.
61. Takechi T., Okabe H., Fujioka A., Murakami Y., Fukushima M. Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn. J. Cancer Res. 89:1998;1144-1153.
62. Tanaka-Nozaki M., Onda M., Tanaka N., Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin. Cancer Res. 7:2001;2783-2787.
63. Tamada H., Fukushima M., Koizumi K.et al. Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver. Int. J. Oncol. 22:2003;359-364.
64. Queener S.F., Morris H.P., Weber G. Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas. Cancer Res. 31:1971;1004-1009.
65. Jiang W., Lu Z., He Y., Diasio R.B. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma. implication in 5-fluorouracil-based chemotherapy Clin. Cancer Res. 3:1997;395-399.
66. Yamashita K., Mikami Y., Ikeda M.et al. Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Lett. 188:2002;231-236.
67. Ichikawa W., Uetake H., Shirota Y.et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin. Cancer Res. 9:2003;786-791.
68. Ichikawa W., Uetake H., Shirota Y.et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br. J. Cancer. 89:2003;1486-1492.
69. Gamelin E., Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer - status of the art. Crit. Rev. Oncol. Hematol. 30:1999;71-79.
70. Katona C., Kralovászky J., Rosta A.et al. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology. 55:1998;468-474.
71. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98:1996;610-615.
72. van Kuilenburg A.B.P., Vreken P., Beex L.V.A.M.et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur. J. Cancer. 33:1997;2258-2264.
73. Kouwaki M., Hamajima N., Sumi S.et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin. Cancer Res. 4:1998;2999-3004.
74. Collie-Duguid E.S.R., Etienne M.C., Milano G.A., McLeod H.L. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 10:2000;217-223.
75. Johnson M.R., Hageboutros A., Wang K., High L., Smith J.B., Diasio R.B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res. 5:1999;2006-2011.
76. van Kuilenburg A.B.P., Haasjes J., Richel D.J.et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity. identification of new mutations in the DPD gene Clin. Cancer Res. 6:2000;4705-4712.
77. van Kuilenburg A.B.P., Muller E.W., Haasjes J.et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil. frequency of the common IVS14+1G>A mutation causing DPD deficiency Clin. Cancer Res. 7:2001;1149-1153.
78. Raida M., Schwabe W., Häusler P.et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7:2001;2832-2839.
79. Johnson M.R., Wang K., Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8:2002;768-774.
80. van Kuilenburg A.B.P., Meinsma J.R., Zoetekouw L., van Gennip A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency. high prevalence of the IVS14+1G>a mutation Int. J. Cancer. 101:2002;253-258.
81. van Kuilenburg A.B.P., Baars J.W., Meinsma J.R., van Gennip A.H. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann. Oncol. 14:2003;341-342.
82. van Kuilenburg A.B.P., Meinsma J.R., Zoetekouw L., van Gennip A.H. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics. 12:2002;555-558.
83. Milano G.A., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer. 79:1999;627-630.
84. Johnson M.R., Diasio R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 41:2001;151-157.
85. Lu Z.H., Zhang R.W., Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver. population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy Cancer Res. 53:1993;5433-5438.
86. Milano G.A., Etienne M.C., Cassuto-Viguier E.et al. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10:1992;1171-1175.
87. Sloan J.A., Goldberg R.M., Sargent D.J.et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 20:2002;1491-1498.
88. Dobritzsch D., Schneider G., Schnackerz K.D., Lindqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 20:2001;650-660.
89. van Kuilenburg A.B.P., Dobritzsch D., Meinsma J.R.et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J. 364:2002;157-163.
90. Takai S., Kimura S., Gonzalez F.J., Yamada K. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridisation. Genomics. 24:1994;613-614.
91. Wei X., Elizondo G., Sapone A., McLeod H.L., Raunio H., Gonzalez F.J. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 51:1998;391-400.
92. van Kuilenburg A.B.P., Vreken P., Abeling N.G.G.M.et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Human Genetics. 104:1999;1-9.
93. van Kuilenburg A.B.P., Meinsma J.R., Poll-The B.T., Zoetekouw L., van Gennip A.H. Identification of a novel disease-causing mutation (100delA) in the dihydropyrimidine dehydrogenase gene. Int. Arch. Biocsi. 1:2002;1096-1100.
94. Yamaguchi K., Arai Y., Kanda Y., Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn. J. Cancer Res. 92:2001;337-342.
95. Vreken P., van Kuilenburg A.B.P., Meinsma J.R.et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis. 19:1996;645-654.
96. Ridge S.A., Sludden J., Brown O.et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 46:1998;151-156.
97. Stott M.K., Fellowes A.P., Upton J.D., Burt M.J., George P.M. Common DPYD mutation associated with 5-fluorouracil toxicity detected by PCR-mediated site-directed mutagenisis. Clin. Chem. 46:2000;309-310.
98. Nauck M., Gierens H., März W., Wieland H. Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin. Biochem. 34:2001;103-105.
99. Ahluwalia R., Freimuth R., McLeod H.L., Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin. Chem. 49:2003;1661-1664.
100. Ezzeldin H., Okamoto Y., Johnson M.R., Diasio R.B. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal. Biochem. 306:2002;63-73.
101. Fischer J., Schwab M., Eichelbaum M., Zanger U.M. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet. Test. 7:2003;97-105.
102. Gross E., Seck K., Neubauer S.et al. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int. J. Oncol. 22:2003;325-332.
103. van Kuilenburg A.B.P., van Lenthe H., Tromp A., Veltman P.C.J., van Gennip A.H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 46:2000;9-17.
104. Gamelin E., Boisdron-Celle M., Guérin-Meyer V.et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer. a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage J. Clin. Oncol. 17:1999;1105-1110.
105. Behnke D., Raida M., Kliche K.-O., Pichlmeier U. Reply. Clin. Cancer Res. 8:2002;1315-1316.
106. Altman D.G. Calculations. Practical Statistics for Medical Research. 1991;Chapman and Hall, London. 414-416.
107. Malet-Martino M., Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1). a review Oncologist. 7:2002;288-323.
108. Toffoli G., Veronesi A., Boiocchi M., Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann. Oncol. 11:2000;373-374.
109. Pullarkat S.T., Stoehlmacher J., Ghaderi V.et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1:2001;65-70.
110. van Kuilenburg A.B.P., Meinsma J.R., Zonnenberg B.A.et al. Dihydropyrimidinase deficiency and severe 5-Fluorouracil toxicity. Clin. Cancer Res. 9:2003;4363-4367.
111. Kornmann M., Link K.H., Galuba I.et al. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J. Gastrointest. Surg. 6:2002;331-337.
112. Etienne M.C., Chazal M., Laurent-Puig P.et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy. phenotypic and genotypic analyses J. Clin. Oncol. 20:2002;2832-2843.
113. Terashima M., Irinoda T., Fujiwara H.et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res. 22:2002;761-768.
114. Takabayashi A., Iwata S., Kawai Y.et al. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol. 17:2000;889-895.
115. Ishikawa Y., Kubota T., Otani Y.et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res. 19:1999;5635-5640.
116. Nozawa H., Tsukui H., Nishida K., Yakumaru K., Nagawa H., Sekikawa T. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother. Pharmacol. 49:2002;267-273.
117. Miyamoto S., Boku N., Ohtsu A.et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int. J. Oncol. 17:2000;653-658.
118. Terashima M., Fujiwara H., Takagane A.et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur. J. Cancer. 38:2002;2375-2381.
119. Nakagawa T., Tanaka F., Takata T.et al. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur+Uracil) in patients with p-stage I nonsmall-cell lung cancer. J. Surg. Oncol. 81:2002;87-92.
120. Fujiwaki R., Hata K., Nakayama K., Fukumoto M., Miyazaki K. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J. Clin. Oncol. 18:2000;3946-3951.
121. Horiguchi J., Takei H., Koibuchi Y.et al. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br. J. Cancer. 86:2002;222-225.
122. Hoque M.O., Kawamata H., Nakashiro K.I.et al. Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer. Int. J. Oncol. 19:2001;953-958.
123. Kawasaki G., Yoshitomi I., Yanamoto S., Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma. an immunohistochemical and clinicopathologic study Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 94:2002;717-723.
124. Mizutani Y., Wada H., Fukushima M.et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur. J. Cancer. 37:2001;569-575.
125. Çelik L., Kars A., Guc D., Tekuzman G., Ruacan S. Dihydropyrimidine dehydrogenase enzyme deficiency. clinical and genetic assessment of prevalence in Turkish cancer patients Cancer Invest. 20:2002;333-339.